Pacira BioSciences announced solid first quarter 2026 financial results with a 5% revenue increase to $177 million, driven by growth across its product portfolio including EXPAREL, ZILRETTA, and iovera°. The company highlighted successful execution of its 5x30 strategy aimed at long-term value creation, with stock up over 30% since its launch. Pacira is urging shareholders to vote for its highly qualified board nominees to prevent activist investor DOMA Perpetual from disrupting its strategic plan, which includes cost cuts and an immediate sale. The company remains confident in its growth trajectory and pipeline advancements with key clinical readouts expected later in 2026.
A three-day online training on Pharmaceutical Regulatory Affairs in Asia is scheduled for October 20-22, 2026, aiming to help professionals understand diverse regulatory requirements across major Asian markets including China, India, Korea, and ASEAN...
The global workwear market, valued at $265.12 billion in 2025, is expected to grow to $344.71 billion by 2031 with a 4.5% CAGR. Growth is fueled by rising corporate employment worldwide, especially in Asia-Pacific, and increased focus on professional...
The global microalgae-based aquafeed market is projected to grow from $320 million in 2026 to $481 million by 2031, at an 8.5% CAGR. Key growth drivers include rapid cost reductions in closed photobioreactor farming, making algae competitive with fis...
The global consumer finance market is projected to expand from $9.87 trillion in 2025 to $14.08 trillion by 2031, growing at a 6.17% CAGR. Key growth drivers include embedded finance at point-of-sale, which boosts credit uptake by integrating lending...
Xcel Brands has signed a licensing agreement with KBL Group to produce ready-to-wear collections for OFF/DUTY by Coco Rocha, a fashion brand created with supermodel Coco Rocha. KBL Group will handle sourcing, product development, manufacturing, and s...
